The use of autologous hematopoietic SCT (auto-HSCT) has expanded to include older patients. Increasing age is a well-appreciated risk factor for the development of atrial fibrillation and/or atrial flutter (AF/AFL) in the general population. As more elderly patients undergo auto-HSCT, the risk of developing AF/AFL post transplant may also increase. However, few data evaluating other risk factors for the development of AF/AFL following auto-HSCT exist. Therefore, we performed a retrospective study to determine the incidence of AF/AFL following auto-HSCT and to determine the risk factors associated with the development of AF/ AFL. Patients who developed AF/AFL were compared with a group of patients who received auto-HSCT within the same time period (April 1999 to May 2005 and were within 5 years of age. Of the 516 patients who underwent auto-HSCT at the University of Nebraska Medical Center 44 (8.5%) developed AF/AFL at a median time of 4 days (range, days 1-9) following auto-HSCT. In multivariate analysis, risk factors for developing AF/AFL were older age, odds ratio and 95% CI of 1.14 (1.07-1.21), elevated serum creatinine level, 2.69 (1.00-7.22), history of previous arrhythmia, 9.33 (3.01-28.99), and history of previous mediastinal irradiation, 11.12 (1.33-92.96).
INTRODUCTION
Previous investigations have found that the incidence of cardiac complications following hematopoietic SCT (HSCT) varies between 5 and 10%. 1 Specific HSCT-related cardiac events include CY-induced hemorrhagic pericarditis or acute cardiomyopathy, 2 thiotepa-related acute myocarditis 3 and bradyarrhythmias during infusion of stem cells cryopreserved with DMSO. 4 The reported incidence of cardiac arrhythmias following HSCT ranges from 4.1 to 7.4%. [5] [6] [7] Hidalgo and colleagues found that older patients with a diagnosis of non Hodgkin's lymphoma are at increased risk for developing supraventricular tachyarrhythmias (defined as AF/AFL or regular narrow complex tachycardia). Data regarding further risk factors for development of AF/AFL following HSCT are scarce.
In general, the mechanism of AF/AFL is understood to be secondary to intra-atrial reentry. Pathology, either structural or biochemical, can result in conduction abnormalities and predispose patients to AF/AFL.
Identifying patients at high risk for AF/AFL in HSCT could be of potential benefit if strategies to decrease the incidence of AF/AFL and its morbidity could be developed. Therefore, we conducted a retrospective study to determine the incidence, risk factors and outcomes associated with the development of AF/AFL after auto-HSCT. 
MATERIALS AND METHODS

Variables analyzed
The following variables were obtained: age at the time of transplant, gender, diagnosis, disease stage at transplant, conditioning regimen, year of transplant, previous medical history including cardiac history (coronary artery disease, congestive heart failure, hypertension, hyperlipidemia, previous arrhythmias, smoking, kidney disease, use of beta blocker, use of calcium channel inhibitors or digoxin, use of mediastianal irradiation, previous coronary artery bypass surgery (CABG)), pre-transplant cardiology work-up (EKG, evaluation of ejection fraction), and electrolyte abnormalities immediately following auto-HSCT. The primary outcome of interest was the development of AF/AFL. Other outcomes evaluated include length of hospital stay (time from stem cell infusion to hospital discharge) and 100-day OS (defined as death from any cause within 100 days post auto-HSCT).
Statistical methods
Univariate comparisons of patient-, disease-and transplant-related characteristics, as well as length of hospital stay between groups were performed using the w 2 test or the Wilcoxon test. The Kaplan-Meier method was used to estimate the probability of survival at 100 days and groups were compared using the log-rank test. Potential risk factors shown in Table 1 were entered in a multivariate analysis using stepwise logistic regression modeling for the odds of developing AF within 30 days post auto-HSCT. Laboratory and ancillary tests that were considered as risk factors were categorized into abnormal/normal or present/absent according to standard parameters. Only variables with a P-value of p0.05 were retained in the final model.
RESULTS
Patient characteristics
Between April 1999 and May 2005, 516 patients underwent auto-HSCT at the UNMC. Of these, 44 patients (overall incidence of 8.5%), including 29 males and 15 females developed AF/AFL at a median of 4 days (range: 1-9) following auto-HSCT. Of the 472 auto-HSCT patients who did not develop AF/AFL, we identified 179 patients with similar characteristics for which auto-HSCT was performed and were within ±5 years of age of the cases. The characteristics of the cases and the comparison group are summarized in Table 1 . Patients who developed AF/AFL were more likely to be older (median age 63 years (range: 50-72) versus 57 (range: 49-72); Po0.001). Additionally, patients who developed AF/AFL were also more likely to have: history of arrhythmia (23 versus 4%), history of kidney disease (16 versus 7%), used calcium channel blockers (9 versus 2%), received mediastinal irradiation (9 versus 1%) and undergone CABG (7 versus 1%). Patients who developed AF/AFL were also more likely to have low serum magnesium levels (11 versus 3%), and have elevated serum creatinine (25 versus 10%) within the first 4 days after stem cell infusion. Forty-five percent of the patients who developed AF/AFL versus none of those in the comparison group who had echocardiograms had an enlarged left atrium by echocardiogram before undergoing HSCT.
On multivariate analysis evaluating age at the time of transplant (Po0.001), elevated serum creatinine within 4 days after auto-HSCT (P ¼ 0.05), previous history of arrhythmia (o0.001) and history of receiving mediastinal irradiation (P ¼ 0.03) were all associated with an increased risk of developing AF/AFL (Table 2) .
Outcomes
We did not observe any statistically significant difference in the median length of hospital stay between the cases and controls (13 days versus 12 days; P ¼ 0.13). Patients who developed AF/AFL did not have an inferior survival at 100 days post auto-HSCT as compared with those who did not develop AF/AFL (90 versus 96%, log-rank P ¼ 0.25).
DISCUSSION
We found that older patients, patients with renal insufficiency, those with a history of a previous arrhythmia, or mediastinal irradiation were more likely to develop AF/AFL in the immediate post-HSCT period. The overall incidence of AF/AFL was 8.5% manifesting at a median time of 4 days (range: 1-9) following auto-HSCT. The incidence of AF/AFL at our center is comparable to those previously reported in the literature with incidence rates of 4.1-7.6% in the post-HSCT period. [5] [6] [7] We feel however that this may be an underestimate of the true incidence of AF/AFL, since cardiac monitors are not routinely utilized during the peritransplant period and some patients may have had short periods of asymptomatic AF/AFL that did not require medical intervention. This would be unlikely to affect outcome and prognosis though if such low burden.
Like the findings of Hidalgo et al., 7 we found that patients with AF/AFL were more likely to be older. Our findings that patients with an elevated creatinine level, prior mediastinal radiation or a history of previous arrhythmia were more likely to develop AF/ AFL, have not been described previously as potential risk factors for the development of AF/AFL in the post auto-HSCT period. [8] [9] [10] In our study, development of AF/AFL was not associated with a longer hospital stay, or inferior survival at 100 days. In contrast, Hidalgo et al., whose study included both allogeneic and autologous HSCT, found that development of AF/AFL prolonged hospitalization and predicted for higher 30-day mortality. This difference in outcomes may be related to the type of HSCT, as our study involved only patients undergoing auto-HSCT. Future aims will be directed at allogeneic-HSCT to define risk factors for AF/ AFL, using in part those identified in this study.
Certain limitations of our study should be considered when interpreting the results. Our findings were based on patients undergoing HSCT at a single institution and institutional practices for selection of patients for HSCT and monitoring during the peri-transplant period may account for some of the differences between our findings and data currently existing in the literature. Despite this, we feel that since our results broadly agree with existing data they represent true findings that need to be explored further.
Further delineation of factors involved in the development of AF/AFL could lead to 'risk score' models to help practitioners identify vulnerable patients and potentially initiate prophylactic treatment. Such practices have been validated and are in place in cardiology with prophylactic treatment utilizing amiodarone before CABG 11 to decrease morbidity and mortality of patients. Limiting exposure to minimize side effects and toxicities of beta-blockers, calcium channel blockers or anti-arrhythmics would be of importance in this group of patients and justification for only using in high-risk patients for development of AF/AFL while undergoing HSCT.
In conclusion, we found that AF/AFL complicated B8.5% of auto-HSCT cases. Older age, previous arrhythmia, previous mediastinal irradiation and an elevated creatinine level predicted for the development of AF/AFL. While AF/AFL did not change survival in our study involving auto-HSCT, further evaluation in allogeneic HSCT may be warranted as prior studies with allogeneic patient have demonstrated differences in outcomes. Utilizing the risk factors identified in this study may be of benefit to guide practitioners in identifying patients at higher risk for AF/AFL and adjusting management as needed in the setting of HSCT. 
